PILL News and Press, Direxion Daily Pharmaceutical & Medical Bull 3X Shares From 01/15/24

2024-01-15 12:40:00 ET Summary All decisions around investing, everything we're seeing everyone doing is now colored by the rate situation. Artificial intelligence is a constantly growing and transforming phenomenon. Unlike artificial intelligence, a lot of the most exciting a...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:27:00 ET Summary Horiba is likely undervalued due to it being under followed, and offers a rare combination of a quality business at an attractive price. The company has high market share in specialized devices in various industries, including automotive, process &am...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...

2023-12-21 15:03:30 ET More on Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X Shares For further details see: Direxion Daily Pharmaceutical & Medical Bull 3X Shares declares quarterly distribution of $0.0383

2023-12-21 08:25:00 ET Summary Given strong recent market returns and another wave of capital inflows, the backdrop is probably not enough to lead to strong tactical performance from risk assets. The US has a more favorable demographic trend; its working-age population is expected...

2023-12-20 06:19:00 ET Summary Can the Magnificent 7 continue to rally into 2024? How the Magnificent 7's rise compares to the dot-com bubble. Why the rise in tech stocks highlights shortcomings for the markets. The rise of the Magnificent 7 tech stocks has been a ke...

2023-12-09 03:00:00 ET Summary The global markets experienced high volatility in 2023 due to factors such as high interest rates, bank failures, and a surge in bond yields. The macro environment in 2024 is expected to be complex and interesting, with rewards for investors who are ...